Huge news: FDA approval today for suzetrigine, the first new drug approval for acute (not chronic) pain in decades and, critically, a non-opioid analgesic:
edition.cnn.com/2025/01/30/h...
edition.cnn.com/2025/01/30/h...
FDA approves first new type of pain medication in 25 years | CNN
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
edition.cnn.com
January 31, 2025 at 4:28 AM
Huge news: FDA approval today for suzetrigine, the first new drug approval for acute (not chronic) pain in decades and, critically, a non-opioid analgesic:
edition.cnn.com/2025/01/30/h...
edition.cnn.com/2025/01/30/h...
“Basic neuroscience hasn’t produced new drugs.” 💊
Not true - zuranolone (PPD), suzetrigine (pain), gepants (migraine), and more... were born out of a long arc of studies in the lab.
I wrote a Perspective on why this matters. @thetransmitter.bsky.social
www.thetransmitter.org/drug-develop...
Not true - zuranolone (PPD), suzetrigine (pain), gepants (migraine), and more... were born out of a long arc of studies in the lab.
I wrote a Perspective on why this matters. @thetransmitter.bsky.social
www.thetransmitter.org/drug-develop...
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
www.thetransmitter.org
December 15, 2025 at 3:15 PM
“Basic neuroscience hasn’t produced new drugs.” 💊
Not true - zuranolone (PPD), suzetrigine (pain), gepants (migraine), and more... were born out of a long arc of studies in the lab.
I wrote a Perspective on why this matters. @thetransmitter.bsky.social
www.thetransmitter.org/drug-develop...
Not true - zuranolone (PPD), suzetrigine (pain), gepants (migraine), and more... were born out of a long arc of studies in the lab.
I wrote a Perspective on why this matters. @thetransmitter.bsky.social
www.thetransmitter.org/drug-develop...
🧪 The FDA just approved suzetrigine (Journavx), a sodium-channel blocker that matches opioid pain relief without addiction risks. A breakthrough 20+ years in the making, it signals a shift in pain medicine. 🩺 🛟 www.nature.com/articles/d41...
US drug agency approves potent painkiller — the first non-opioid in decades
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
www.nature.com
January 31, 2025 at 3:37 PM
🧪 The FDA just approved suzetrigine (Journavx), a sodium-channel blocker that matches opioid pain relief without addiction risks. A breakthrough 20+ years in the making, it signals a shift in pain medicine. 🩺 🛟 www.nature.com/articles/d41...
On Thursday, the US Food and Drug Administration approved suzetrigine for short-term pain management, making it the first non-opioid pain drug given a regulatory nod in more than 20 years.
https://go.nature.com/40SKITt
https://go.nature.com/40SKITt
US drug agency approves potent painkiller — the first non-opioid in decades
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
go.nature.com
January 31, 2025 at 9:00 AM
On Thursday, the US Food and Drug Administration approved suzetrigine for short-term pain management, making it the first non-opioid pain drug given a regulatory nod in more than 20 years.
https://go.nature.com/40SKITt
https://go.nature.com/40SKITt
Unlike opioids, which work by latching onto receptor proteins on nerves in the central nervous system, suzetrigine works only in peripheral nerves—that is, those outside the brain and spinal cord.
FDA approves first non-opioid pain medicine in more than 20 years
The drug, Journavx (suzetrigine), inhibits an ion channel in peripheral nerves.
arstechnica.com
February 3, 2025 at 6:30 PM
Unlike opioids, which work by latching onto receptor proteins on nerves in the central nervous system, suzetrigine works only in peripheral nerves—that is, those outside the brain and spinal cord.
The good news is there's a new option for acute/postsurgical pain (suzetrigine) that is not an opioid! The bad news is it doesn't work on chronic pain :/
October 8, 2025 at 3:33 AM
The good news is there's a new option for acute/postsurgical pain (suzetrigine) that is not an opioid! The bad news is it doesn't work on chronic pain :/
The FDA recently approved a novel pain medication developed by Vertex, Journavx (suzetrigine)
www.fda.gov/news-events/...
1/n
www.fda.gov/news-events/...
1/n
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
www.fda.gov
February 22, 2025 at 10:21 AM
The FDA recently approved a novel pain medication developed by Vertex, Journavx (suzetrigine)
www.fda.gov/news-events/...
1/n
www.fda.gov/news-events/...
1/n
Suzetrigine is a sodium channel inhibitor that suppresses the ability of nerves to communicate pain signals to the brain. (It also says really interesting things about the difference between acute and chronic pain for it only to work on one of them.)
January 31, 2025 at 4:28 AM
Suzetrigine is a sodium channel inhibitor that suppresses the ability of nerves to communicate pain signals to the brain. (It also says really interesting things about the difference between acute and chronic pain for it only to work on one of them.)
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research, writes @alexkwan.bsky.social.
www.thetransmitter.org/drug-develop...
#neuroskyence
www.thetransmitter.org/drug-develop...
#neuroskyence
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
www.thetransmitter.org
December 15, 2025 at 7:12 PM
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research, writes @alexkwan.bsky.social.
www.thetransmitter.org/drug-develop...
#neuroskyence
www.thetransmitter.org/drug-develop...
#neuroskyence
I would honestly recommend poor metabolizers push their insurance to cover suzetrigine, which is only useful in acute/post-surgical pain, not chronic, but is a different metabolism and also not an opiate.
February 23, 2026 at 11:04 PM
I would honestly recommend poor metabolizers push their insurance to cover suzetrigine, which is only useful in acute/post-surgical pain, not chronic, but is a different metabolism and also not an opiate.
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, addiction-free pain-relief treatment.
First new non-opioid painkiller approved in the US for decades – here’s how it works
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, addiction-free pain-relief treatment.
tcnv.link
February 6, 2025 at 6:26 AM
The FDA has approved suzetrigine, a groundbreaking non-opioid painkiller that targets pain at its source, offering a safer, addiction-free pain-relief treatment.
In January, the FDA approved a new non-opioid painkiller.
In today’s episode, we’ll explore the science behind the first new pain medicine in over two decades.
Listen here 🎧: https://buff.ly/40ZyPKh
In today’s episode, we’ll explore the science behind the first new pain medicine in over two decades.
Listen here 🎧: https://buff.ly/40ZyPKh
February 17, 2025 at 7:29 PM
In January, the FDA approved a new non-opioid painkiller.
In today’s episode, we’ll explore the science behind the first new pain medicine in over two decades.
Listen here 🎧: https://buff.ly/40ZyPKh
In today’s episode, we’ll explore the science behind the first new pain medicine in over two decades.
Listen here 🎧: https://buff.ly/40ZyPKh
Exciting new work on #suzetrigine effects on spontaneously active human DRG neurons from patients/donors with a pain history. Short story is that suzetrigine is remarkably effective at blocking spontaneous activity. Collab with Dougherty lab at MDACC!
Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons https://www.biorxiv.org/content/10.1101/2025.04.09.648014v1
April 15, 2025 at 11:29 PM
Exciting new work on #suzetrigine effects on spontaneously active human DRG neurons from patients/donors with a pain history. Short story is that suzetrigine is remarkably effective at blocking spontaneous activity. Collab with Dougherty lab at MDACC!
💊💊💊 FDA approves Vertex's Journavx, the first non-opioid pain drug in a new class for moderate to severe acute pain. A historic milestone for pain management.
Journavx (suzetrigine) targets NaV1.8 sodium channels in pain-sensing neurons--proteins that regulate the flow of ions in neurons
Journavx (suzetrigine) targets NaV1.8 sodium channels in pain-sensing neurons--proteins that regulate the flow of ions in neurons
January 31, 2025 at 3:17 PM
💊💊💊 FDA approves Vertex's Journavx, the first non-opioid pain drug in a new class for moderate to severe acute pain. A historic milestone for pain management.
Journavx (suzetrigine) targets NaV1.8 sodium channels in pain-sensing neurons--proteins that regulate the flow of ions in neurons
Journavx (suzetrigine) targets NaV1.8 sodium channels in pain-sensing neurons--proteins that regulate the flow of ions in neurons
In clinical studies (pubmed.ncbi.nlm.nih.gov/37530822/), Suzetrigine reduced pain more effectively than placebo in patients undergoing “tummy tuck” or bunion surgery.
27/n
27/n
February 22, 2025 at 10:43 AM
In clinical studies (pubmed.ncbi.nlm.nih.gov/37530822/), Suzetrigine reduced pain more effectively than placebo in patients undergoing “tummy tuck” or bunion surgery.
27/n
27/n
4/
Also in the mix: suzetrigine, a new non-opioid painkiller. It blocks a sodium channel (NaV1.8) on peripheral pain nerves, so signals never reach the brain. First genuinely new class of analgesic in over 25 years, after decades of targeting the same pathway.
Also in the mix: suzetrigine, a new non-opioid painkiller. It blocks a sodium channel (NaV1.8) on peripheral pain nerves, so signals never reach the brain. First genuinely new class of analgesic in over 25 years, after decades of targeting the same pathway.
September 3, 2026 at 8:14 PM
4/
Also in the mix: suzetrigine, a new non-opioid painkiller. It blocks a sodium channel (NaV1.8) on peripheral pain nerves, so signals never reach the brain. First genuinely new class of analgesic in over 25 years, after decades of targeting the same pathway.
Also in the mix: suzetrigine, a new non-opioid painkiller. It blocks a sodium channel (NaV1.8) on peripheral pain nerves, so signals never reach the brain. First genuinely new class of analgesic in over 25 years, after decades of targeting the same pathway.
from what I understand the main usage case for suzetrigine/ journavx is surgery recovery, so if you have that coming up and want to avoid opioids that might be a good thing for you. expensive as fuck though
October 1, 2026 at 5:15 PM
from what I understand the main usage case for suzetrigine/ journavx is surgery recovery, so if you have that coming up and want to avoid opioids that might be a good thing for you. expensive as fuck though
The FDA was barred from issuing press releases, w/ the exception of emergency news. Was this approval really an emergency?
When you only release favorable news, that’s called propaganda.
New non-opioid painkiller approved by US health agency www.bbc.com/news/article...
When you only release favorable news, that’s called propaganda.
New non-opioid painkiller approved by US health agency www.bbc.com/news/article...
Vertex: New non-opioid painkiller Journavx approved by US FDA
New drug suzetrigine, known by its brand name Journavx, has been approved to treat moderate to severe pain.
www.bbc.com
February 2, 2025 at 5:36 AM
The FDA was barred from issuing press releases, w/ the exception of emergency news. Was this approval really an emergency?
When you only release favorable news, that’s called propaganda.
New non-opioid painkiller approved by US health agency www.bbc.com/news/article...
When you only release favorable news, that’s called propaganda.
New non-opioid painkiller approved by US health agency www.bbc.com/news/article...
Vertex Pharmaceuticals’ suzetrigine, which will be marketed under the name Journavx, targets specific sodium channels that help pass signals on from the site of pain. cen.acs.org/pharmaceutic... #biosky
FDA approves new nonopioid pain medication, hailed a 'triumph'
Vertex’s suzetrigine is a paradigm shift in pain management, the firm’s CEO says
cen.acs.org
February 1, 2025 at 9:41 PM
Vertex Pharmaceuticals’ suzetrigine, which will be marketed under the name Journavx, targets specific sodium channels that help pass signals on from the site of pain. cen.acs.org/pharmaceutic... #biosky
The FDA has approved the first new class of non-opioid pain medication in decades. Alternatives to effectively manage pain are desperately needed. This is welcome news.
www.nature.com/articles/d41...
www.nature.com/articles/d41...
US drug agency approves potent painkiller — the first non-opioid in decades
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
www.nature.com
February 2, 2025 at 6:34 PM
The FDA has approved the first new class of non-opioid pain medication in decades. Alternatives to effectively manage pain are desperately needed. This is welcome news.
www.nature.com/articles/d41...
www.nature.com/articles/d41...
A long-awaited nonopioid pain drug has won approval from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain.
Nonopioid drug for acute pain wins FDA approval
Ongoing trials will reveal whether suzetrigine is also effective against chronic pain
scim.ag
January 31, 2025 at 6:21 PM
A long-awaited nonopioid pain drug has won approval from the U.S. Food and Drug Administration (FDA) to treat moderate to severe short-term pain.
The FDA has signed off on the first new type of pain reliever to be approved in more than two decades.
FDA approves first new type of pain medication in 25 years | CNN
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
cnn.it
January 30, 2025 at 11:14 PM
The FDA has signed off on the first new type of pain reliever to be approved in more than two decades.
Never forget about training. The 1st author on the suzetrigine paper got his start in research as a postbac in the intramural program at NIH, a PhD at Columbia and a postdoc with Nobel laureate (although not at the time) David Julius at UCSF.
www.linkedin.com/in/jeremiah-...
/fin
www.linkedin.com/in/jeremiah-...
/fin
www.linkedin.com
February 22, 2025 at 10:49 AM
Never forget about training. The 1st author on the suzetrigine paper got his start in research as a postbac in the intramural program at NIH, a PhD at Columbia and a postdoc with Nobel laureate (although not at the time) David Julius at UCSF.
www.linkedin.com/in/jeremiah-...
/fin
www.linkedin.com/in/jeremiah-...
/fin
Happy #PharmPhriday! FDA approved the first-in-class non-opioid analgesic for treating moderate to severe acute pain in adults. The drug Journavx (suzetrigine) is an oral, selective inhibitor of a type of sodium ion channel called Nav1.8, expressed in sensory neurons.
#MedSky #PublicHealth 🧪
#MedSky #PublicHealth 🧪
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.
www.fda.gov
January 31, 2025 at 5:58 PM
Happy #PharmPhriday! FDA approved the first-in-class non-opioid analgesic for treating moderate to severe acute pain in adults. The drug Journavx (suzetrigine) is an oral, selective inhibitor of a type of sodium ion channel called Nav1.8, expressed in sensory neurons.
#MedSky #PublicHealth 🧪
#MedSky #PublicHealth 🧪